# DrNow (닥터나우)
**Last Researched:** 2026-02-27

## Recent Developments (2025-2026)

### Business Scale
- **5.6M users** (per portfolio documentation)
- #1 non-face-to-face telemedicine app in Korea
- Series B: **W400B (~00M)** funding target/completed

### Product & Services
- Remote consultation and prescription drug delivery
- Key specialties: General medicine, pediatrics, dermatology (acne, hair loss), weight management
- Weekend and holiday consultations available (including pediatrics, OBGYN)
- Prescription medications + delivery service
- Weight management injections (Wegovy/위고비, Mounjaro/마운자로, etc.)
- Operates under Korean telemedicine regulations

### Market Position
- **Leader in Korean telemedicine market** - "비대면 진료 1위"
- Platform enables patients to receive medical care anytime, anywhere
- Strong focus on convenience and accessibility
- Competitive advantages: Brand recognition, user base, regulatory compliance

### Regulatory Context (Korea)
- Operating within Korea's telemedicine framework
- Remote consultations + prescription delivery legally permitted
- Differentiation from traditional in-person care

### Next Steps to Monitor
- Series B funding close status (W400B target)
- User growth trajectory beyond 5.6M
- Expansion to additional medical specialties
- Revenue and unit economics disclosure
- Potential IPO timeline (typical path for Korean healthtech unicorns)
- Competition from Naver/Kakao healthtech initiatives
- Regulatory changes in Korean telemedicine landscape